1991
Behavioral and receptor binding analysis of the α2-adrenergic agonist, 5-bromo-6 [2-imidazoline-2-YL amino] quinoxaline (UK-14304): evidence for cognitive enhancement at an α2-adrenoceptor subtype
Arnsten A, Leslie FM. Behavioral and receptor binding analysis of the α2-adrenergic agonist, 5-bromo-6 [2-imidazoline-2-YL amino] quinoxaline (UK-14304): evidence for cognitive enhancement at an α2-adrenoceptor subtype. Neuropharmacology 1991, 30: 1279-1289. PMID: 1686301, DOI: 10.1016/0028-3908(91)90024-6.Peer-Reviewed Original Research
1988
The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes
Arnsten A, Cai J, Goldman-Rakic P. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. Journal Of Neuroscience 1988, 8: 4287-4298. PMID: 2903226, PMCID: PMC6569464, DOI: 10.1523/jneurosci.08-11-04287.1988.Peer-Reviewed Original ResearchConceptsAlpha-2 receptor subtypesB-HT920Alpha-2 agonistsReceptor subtypesRank order potencyLow dosesDose-response profilesBlood pressureSide effectsHigh dosesAlpha-2 adrenergic agonistsOrder potencyHypotensive side effectsSedative side effectsSubtypes of receptorsAged nonhuman primatesAged rhesus monkeysMemory-enhancing effectsMemory-impairing effectsClonidine effectAgonist guanfacineClonidineAdrenergic agonistsGuanfacineSedation